PMID- 32760668
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and 
      Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience.
PG  - 1095
LID - 10.3389/fonc.2020.01095 [doi]
LID - 1095
AB  - This study aimed to determine the real-world, long-term prognostic impacts, and 
      adverse effects (AEs) of bevacizumab (BEV) in Asian patients with 
      ovarian/tubal/peritoneal cancers. We retrospectively reviewed the medical records 
      of consecutive patients with ovarian/tubal/peritoneal cancer on front-line 
      chemotherapy with or without BEV (Cohort 1) and those who relapsed following 
      chemotherapy and/or BEV (Cohort 2) between 2011 and 2018 in a tertiary medical 
      centre. Patient characteristics, BEV dosages, clinical outcomes, and AEs were 
      analyzed. Hazard ratios for disease progression and death were analyzed using a 
      cox proportional regression model. Benefits of BEV used throughout triweekly, in 
      terms of improved progression-free survival (PFS) and overall survival (OS), were 
      observed at a dosage of 7.5-15 mg/kg among advanced-stage Cohort 1 patients. A 
      progression-free interval of <6 months was the strongest predictor of disease 
      progression and death in advanced-stage patients. BEV throughout and optimal 
      cytoreduction were independent predictors of reduced disease progression. No 
      prognostic advantage was observed between serous and clear cell histologies when 
      BEV was added. Moreover, BEV resulted in improved OS in Cohort 2 patients, 
      especially in the platinum-sensitive subgroup. Most patients had a front-line BEV 
      dosage <10 mg/kg per cycle with <10 treatment cycles. Low rates and grades of 
      BEV-related AEs were observed in both cohorts. BEV used throughout effectively 
      extended PFS and OS in advanced-stage patients with ovarian/tubal/peritoneal 
      cancer. Patients with platinum-sensitive carcinoma, treated with BEV, had a 
      significant improvement in OS and extended PFS. Therefore, BEV can safely be 
      added to chemotherapy for ovarian/tubal/peritoneal cancers.
CI  - Copyright (c) 2020 Wu, Cheng, Shen, Chen, Huang and Chou.
FAU - Wu, Pei-Ying
AU  - Wu PY
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Cheng, Ya-Min
AU  - Cheng YM
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
AD  - Department of Medicine, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Shen, Meng-Ru
AU  - Shen MR
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
AD  - Department of Pharmacology, College of Medicine, National Cheng Kung University, 
      Tainan, Taiwan.
FAU - Chen, Yi-Chun
AU  - Chen YC
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Huang, Yu-Fang
AU  - Huang YF
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
FAU - Chou, Cheng-Yang
AU  - Chou CY
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7372289
OTO - NOTNLM
OT  - bevacizumab
OT  - drug-related side effects
OT  - fallopian cancer
OT  - ovarian cancer
OT  - peritoneal cancer
OT  - platinum sensitivity
OT  - progression
OT  - survival
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
PMCR- 2020/01/01
CRDT- 2020/08/08 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.01095 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jul 14;10:1095. doi: 10.3389/fonc.2020.01095. eCollection 2020.